AVR-235 is a topically available tissue targeted PEGylated small molecule JAK3/TrkA inhibitor for atopic dermatitis, psoriasis and associated pruritus. It blocks key cytokines involved in the pathogenesis of these inflammatory skin conditions, such as IL-2, IL-3, IL-17a, IL-17F and TNF-alpha. The topical nature and specificity of the molecule allows for tissue targeted JAK inhibition with little to no systemic exposure or toxicity.

AVR-235 has been clinically validated in phase I/II studies with no safety signals, while certain histological and biomarker changes indicated drug effects in atopic dermatitis and psoriasis.

AVR-235 has also demonstrated potential as a potent gut-restricted therapy for inflammatory GI tract conditions including Ulcerative Colitis and IBD in preclinical disease model studies, via known JAK3 inhibition mechanisms and TrkA impacts on neurogenic inflammation for potential pain reduction.